Nan Fung Trinity HK Ltd. Buys 35,778 Shares of Protagonist Therapeutics, Inc. $PTGX

Nan Fung Trinity HK Ltd. boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 24.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 180,670 shares of the company’s stock after acquiring an additional 35,778 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Protagonist Therapeutics were worth $15,780,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the business. Smartleaf Asset Management LLC increased its stake in shares of Protagonist Therapeutics by 11.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after purchasing an additional 146 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Parkman Healthcare Partners LLC increased its stake in shares of Protagonist Therapeutics by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock worth $4,109,000 after purchasing an additional 253 shares in the last quarter. Guggenheim Capital LLC increased its stake in shares of Protagonist Therapeutics by 1.6% in the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after purchasing an additional 303 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Up 0.5%

Shares of NASDAQ:PTGX opened at $99.36 on Friday. The company has a 50 day moving average of $99.40 and a 200 day moving average of $89.42. The stock has a market cap of $6.39 billion, a P/E ratio of -54.90 and a beta of 1.89. Protagonist Therapeutics, Inc. has a 12 month low of $42.85 and a 12 month high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The business had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 54,641 shares of the business’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $101.00, for a total value of $5,518,741.00. Following the completion of the transaction, the chief executive officer owned 524,938 shares of the company’s stock, valued at $53,018,738. The trade was a 9.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Asif Ali sold 24,765 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the completion of the transaction, the chief financial officer directly owned 60,753 shares of the company’s stock, valued at approximately $6,332,892.72. This represents a 28.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 138,215 shares of company stock worth $13,866,186. 4.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Truist Financial lifted their target price on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Finally, Wall Street Zen upgraded shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $113.69.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.